Financial information

celebrating 20 years Summarised Group revenue segmental analysis

for the year ended 30 June 2018

2018
R'million
2017
R'million
Change
%
Commercial Pharmaceuticals by customer geography 33 270 31 437 6
Sub-saharan Africa 8 127 7 459 9
Developed Europe 7 434 6 817 9
Australasia 4 816 4 799 0
Latin America 2 929 2 722 8
Developing Europe & CIS 2 780 2 589 7
China 2 415 1 753 38
Japan 1 930 1 932 0
Other Asia 1 401 1 206 16
MENA 877 1 117 (21)
USA & Canada 561 1 043 (46)
Manufacturing revenue by geography of manufacture      
Manufacturing revenue – finished dose form 1 644 2 141 (23)
Developed Europe 636 638 0
Sub-Saharan Africa 532 1 031 (48)
Australasia 464 472 (2)
Latin America 12 100
Manufacturing revenue – active pharmaceutical ingredients 4 591 4 411 4
Developed Europe 4 259 3 976 7
Sub-Saharan Africa 332 435 (24)
Total Manufacturing revenue 6 235 6 552 (5)
Total Pharmaceuticals 39 505 37 989 4
Nutritionals by customer geography 3 091 3 224 (4)
Latin America 1 290 1 462 (12)
Sub-saharan Africa 1 017 967 5
Australasia 715 795 (10)
China 65 100
MENA 4 100
Total revenue 42 596 41 213 3
Summary of regions      
Developed Europe 12 329 11 431 8
Sub-saharan Africa 10 008 9 892 1
Australasia 5 995 6 066 (1)
Latin America 4 231 4 184 1
Developing Europe & CIS 2 780 2 589 7
China 2 480 1 753 41
Japan 1 930 1 932 0
Other Asia 1 401 1 206 16
MENA 881 1 117 (21)
USA & Canada 561 1 043 (46)
Total revenue 42 596 41 213 3

Commercial Pharmaceuticals therapeutic area analysis

2018
Anaesthetics Brands
R’million
Thrombosis Brands
R’million
High Potency & Cytotoxic Brands
R’million
Therapeutic Focused Brands
R’million
Regional Brands
R’million
Total
R’million
By customer geography            
Commercial Pharmaceuticals            
Sub-saharan Africa 143 9 99 251 7 876 8 127
Developed Europe 2 170 3 471 1 417 7 058 376 7 434
Australasia 713 21 477 1 211 3 605 4 816
Latin America 762 71 790 1 623 1 306 2 929
Developing Europe & CIS 434 1 876 406 2 716 64 2 780
China 1 779 616 20 2 415 2 415
Japan 1 213 48 372 1 633 297 1 930
Other Asia 658 151 262 1 071 330 1 401
MENA 156 159 193 508 369 877
USA & Canada 304 8 136 448 113 561
Total Commercial Pharmaceuticals 8 332 6 430 4 172 18 934 14 336 33 270
2017
Anaesthetics Brands
R’million
Thrombosis Brands
R’million
High Potency & Cytotoxic Brands
R’million
Therapeutic Focused Brands
R’million
Regional Brands
R’million
Total
R’million
By customer geography            
Commercial Pharmaceuticals            
Sub-saharan Africa 144 7 126 277 7 182 7 459
Developed Europe 1 700 3 168 1 472 6 340 477 6 817
Australasia 639 25 483 1 147 3 652 4 799
Latin America 605 92 838 1 535 1 187 2 722
Developing Europe & CIS 317 1 714 472 2 503 86 2 589
China 1 453 252 48 1 753 1 753
Japan 1 293 46 408 1 747 185 1 932
Other Asia 429 176 258 863 343 1 206
MENA 231 169 275 675 442 1 117
USA & Canada 254 16 307 577 466 1 043
Total Commercial Pharmaceuticals 7 065 5 665 4 687 17 417 14 020 31 437
% Change
Anaesthetics Brands
%
Thrombosis Brands
%
High Potency & Cytotoxic Brands
%
Therapeutic Focused Brands
%
Regional Brands
%
Total
%
By customer geography            
Commercial Pharmaceuticals            
Sub-saharan Africa (1) 29 (21) (9) 10 9
Developed Europe 28 10 (4) 11 (21) 9
Australasia 12 (16) (1) 6 (1) 0
Latin America 26 (23) (6) 6 10 8
Developing Europe & CIS 37 9 (14) 9 (26) 7
China 22 >100 (58) 38 0 38
Japan (6) 4 (9) (7) 61 0
Other Asia 53 (14) 2 24 (4) 16
MENA (32) (6) (30) (25) (17) (21)
USA & Canada 20 (50) (56) (22) (76) (46)
Total Commercial Pharmaceuticals 18 14 (11) 9 2 6